Concord Biotech IPO Details
Issue Date
--
Price Range
₹741
Lot Size
20
IPO Size
₹1550.59 Cr
Concord Biotech IPO Listing Details
Listing On
18 Aug'23
Issue Price
--
Listed Price
₹ 900.05
Retail Gain/Listing Gain
▲21.46%
Schedule of Concord Biotech IPO
Start date
End date
Allotment of bids
Refund Initiation
Listing on exchange
18/08/2023
Company Background
Concord Biotech Ltd. is an Indian biopharmaceutical company, holding a prominent position among global developers and manufacturers (in terms of volume in 2022) of fermentation-based APIs. These Active Pharmaceutical Ingredients known as APIs, play a crucial role in preventing or curing diseases (Source: F&S Report).
The company also holds a market share of over 20% by volume in 2022, across fermentation-based API products, including mupirocin, sirolimus, tacrolimus, mycophenolate sodium and cyclosporine.
Concord Biotech supplies to over 70 countries including regulated markets, such as the United States, Europe, Japan, and India. In 2016, the company launched its formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded in the United States.
With that, let's take a look at the competitive strengths and risks factors for Concord Biotech Ltd:
Competitive Strengths
Financial track record of rapid growth and consistent profitability
Established presence across the complex fermentation value chain
Global leadership in immunosuppressant APIs
Risk Factors
-
Delays in the supply and transport of raw materials may adversely impact the pricing and supply of end products, thus adversely affecting the business.
-
The company's reputation could be at risk if there are any manufacturing or quality control issues, potentially resulting in a decline in brand prominence.
-
Any slowdown or shutdown of its research and development operations can adversely affect the business.
Key Strategies
-
Continue to increase the API market share and further develop the product portfolio.
-
Increase the presence of existing formulations and expand into new formulations.
-
Grow the CDMO business.
Concord Biotech Ltd
Here are the key financials for Concord Biotech Limited.
How to apply for IPO through ASBA
Kotak Neo
•00m 58 s
Concord Biotech IPO FAQs
The Concord Biotech IPO opens for subscription from [-] to [-], with a total issue size of ₹1550.59 Cr. The IPO price band is ₹741 to ₹0 per share with a lot size of 20. The company aims to list the shares on BSE & NSE on 18-08-2023.
The Concord Biotech IPO will open for subscription on [-] and will close on [-] for investors.
The minimum lot size for the Concord Biotech IPO is 20 equity shares, requiring a minimum investment of ₹[-] for retail investors applying in the IPO.
The price band of the Concord Biotech IPO has been fixed at ₹741 to ₹0 per equity share.
You can apply for the Concord Biotech IPO online through the Kotak Neo Website or the Kotak Neo App using UPI or ASBA during the IPO subscription period.
Concord Biotech IPO allotment will take place on [-].
You can check the Concord Biotech IPO allotment status online on the registrar’s website or on the NSE and BSE IPO allotment pages using your application number, PAN, or demat account details.
Concord Biotech shares will list on the stock exchanges on 18-08-2023.
The Concord Biotech Limited IPO has an issue size of Rs. 1,550.52 crores. The IPO opens for subscription on 4th August and ends on 8th August.
Link Intime India Private Limited is the registrar for this IPO.
You can read more about Concord Biotech Limited and its IPO from the company’s red herring prospectus (RHP) here.
Trending IPOs
17 Apr - 21 Apr'26 | |||||||||
17 Apr - 21 Apr'26 | |||||||||
To be announced | |||||||||
To be announced | |||||||||
To be announced | |||||||||
Trending IPOs
17 Apr - 21 Apr'26 | |||||||||
17 Apr - 21 Apr'26 | |||||||||
To be announced | |||||||||
To be announced | |||||||||
To be announced | |||||||||